Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Cash (2016 - 2025)

Historic Change in Cash for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$12.5 million.

  • Enanta Pharmaceuticals' Change in Cash fell 95829.9% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 8848.93%. This contributed to the annual value of -$5.5 million for FY2025, which is 8848.93% up from last year.
  • Enanta Pharmaceuticals' Change in Cash amounted to -$12.5 million in Q3 2025, which was down 95829.9% from -$15.4 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Cash peaked at $52.6 million during Q3 2021, and registered a low of -$72.5 million during Q2 2021.
  • For the 5-year period, Enanta Pharmaceuticals' Change in Cash averaged around -$1.1 million, with its median value being -$1.8 million (2022).
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 51343.13% in 2021, then crashed by 246662.9% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Change in Cash stood at $41.9 million in 2021, then tumbled by 104.23% to -$1.8 million in 2022, then plummeted by 2466.63% to -$45.5 million in 2023, then soared by 203.65% to $47.1 million in 2024, then plummeted by 126.56% to -$12.5 million in 2025.
  • Its last three reported values are -$12.5 million in Q3 2025, -$15.4 million for Q2 2025, and -$24.7 million during Q1 2025.